ID   NALM-16
AC   CVCL_1834
SY   NALM16; Nalm-16
DR   BioSample; SAMN03473434
DR   cancercelllines; CVCL_1834
DR   Cosmic; 998707
DR   Cosmic; 999758
DR   Cosmic; 1037712
DR   DepMap; ACH-001993
DR   DSMZ; ACC-680
DR   DSMZCellDive; ACC-680
DR   GEO; GSM5137733
DR   PRIDE; PXD023662
DR   Wikidata; Q54907397
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=155647;
RX   PubMed=2140233;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6582512;
RX   PubMed=6928235;
RX   PubMed=8847894;
RX   PubMed=9680106;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=35354797;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 36.7 hours (PubMed=8847894); ~36 hours (DSMZ=ACC-680).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DepMap=ACH-001993; DSMZ=ACC-680
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 17,18
ST   D19S433: 13
ST   D21S11: 29,30 (DSMZ=ACC-680)
ST   D21S11: 30 (DepMap=ACH-001993)
ST   D2S1338: 18
ST   D3S1358: 15,17 (DSMZ=ACC-680)
ST   D3S1358: 17 (DepMap=ACH-001993)
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 20
ST   Penta D: 9,12.4 (DSMZ=ACC-680)
ST   Penta D: 9,13 (DepMap=ACH-001993)
ST   Penta E: 8
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=155647;
RA   Han T., Minowada J.;
RT   "Use of stimulating capacity of mixed lymphocyte reaction (MLR-S) as a
RT   possible marker for the cell-origin of null-cell acute lymphoblastic
RT   leukaemia.";
RL   Immunology 35:333-339(1978).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6928235; DOI=10.1093/jnci/64.3.485;
RA   Kohno S.-i., Minowada J., Sandberg A.A.;
RT   "Chromosome evolution of near-haploid clones in an established human
RT   acute lymphoblastic leukemia cell line (NALM-16).";
RL   J. Natl. Cancer Inst. 64:485-493(1980).
//
RX   PubMed=8847894;
RA   Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K.,
RA   Nakamura H., Amakawa R., Ohno H.;
RT   "Sensitivity to dexamethasone and absence of bcl-2 protein in
RT   Burkitt's lymphoma cell line (Black93) derived from a patient with
RT   acute tumor lysis syndrome: comparative study with other BL and non-BL
RT   lines.";
RL   Leukemia 10:1592-1603(1996).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//